GWPH

GW Pharmaceuticals Plc - American Depositary Shares

144.5582
USD
-0.52%
144.5582
USD
-0.52%
101.0710 179.6500
52 weeks
52 weeks

Mkt Cap 4.02B

Shares Out 28.19M

new Chat
Send me real-time posts from this site at my email

GW Pharma's Price Target Raised To $208 At Cantor

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) to $208/ADS from $182/ADS after additional positive Epidiolex results.

Epidiolex Significance

The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and remarkable consistency” across two distinct forms of epilepsy, LGS and Dravet syndrome.

“The previously disclosed seizure reduction of about 40 percent in three distinct indications was corroborated by fresh data on responder analysis. About 40 percent of patients experience a >=50 percent seizure reduction,” analyst Elemer Piros wrote in a note.

Piros, who has a Buy rating on the shares, said GW dismissed the concern that the drug should be taken with clobazam for efficacy.

“The fact that non-clobazam treated patients received anti-seizure benefit from Epidiolex speaks volumes against the theory,” Piros highlighted.

The company expects to submit a single NDA covering both the LGS and Dravet indications by the end of first half of 2017, followed by an EU submission in the second half of 2017.

Additional Catalysts

Other upcoming catalysts for the stock include data readouts from the adult partial-onset epilepsy study with cannabinoid analogue CBDV in mid-2017 and results from a glioblastoma trial with mixed THC:CBD combination in the first quarter of next year.

At last check, ADRs of the Cambridge, U.K.-based GW Pharma had climbed 6.89 percent on the day to $120.06.